UNVEILING new horizons
Integrated Care for haemophilia and haemoglobinopathies.
As of December 2025, the Novo Nordisk Haemophilia Foundation is expanding and is proudly the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation.
Extending beyond Haemophilia, the Foundation is including people with sickle cell disease or thalassemia to leverage its impact through strategic use of synergies and integrated care models.
Depending on the regional context of the specific project, NNHF addresses one, two, or all three disorders in a combined effort, resulting in quadrupling the number of people that can now access the care they need.
We are leveraging our impact
Responding to community requests and urgent global needs, NNHF is expanding its mission to include haemoglobinopathies (sickle cell disease and thalassaemia) alongside haemophilia. This scale-up has evolved from our two-decade long experience in the field, revealing four key insights:
-
Our integrated care pilots proved right
Over the past five years, NNHF has piloted integrated care models for haemophilia and haemoglobinopathies in more than ten countries. These pilots have demonstrated that combining services leads to earlier diagnosis, better treatment, and more sustainable access to care. Especially in resource-limited settings.
-
Community demand is high
The expansion is a direct response to requests from healthcare professionals and patient communities, particularly in Africa, where the burden of sickle cell disease and thalassaemia is highest.
-
Global health priorities need counterbalance
Haemophilia and haemoglobinopathies are often neglected non-communicable diseases (NCDs). By extending our approach, we are counterbalancing this trend and aligning with national and global strategies to reduce child mortality and strengthen health care systems.
-
Sustainable impact is accelerated
With this step, we have more power to lead our partners to operating self-sufficiently and drive systemic change thanks to coordinated capacity building and solid data-driven advocacy towards authorities and the public.
This effort matters
+10M
people live with haemophilia, sickle cell disease, or thalassaemia. 80%+ in low- and middle-income countries, facing severe barriers to diagnosis and treatment.
3
diseases through one combined approach. Integrated care means earlier diagnosis, streamlined services, and local access to quality infrastructure.
200K
direct beneficiaries annually by 2030. NNHF aims to quadruple their reach through the expansion.
Will this expansion change how NNHF works?
No. We remain committed to all our project partners and to our partnership-based approach. We are not shifting resources. We are adding resources to increase the number of people we reach exponentially.
Yes, sickle cell bends me. But it does not break me.
Questions? Let us provide the answers!
-
What is integrated care?
We can achieve more comprehensive diagnosis and care, build stronger infrastructure, and generate more awareness when addressing multiple blood conditions simultaneously. Coordinated programming in low- and middle-income countries serve healthcare professionals and affected individuals in a more efficient way. Depending on the regional context of the project, NNHF addresses one, two, or all three of the disorders – haemophilia, sickle cell disease, and thalassaemia – in an integrated effort.
-
What is haemophilia?
Haemophilia (bleeding disorder) is a rare, inherited bleeding disorder where the blood does not clot properly. The two main types are Haemophilia A (factor VIII deficiency) and Haemophilia B (factor IX deficiency). It primarily affects males, but females can be carriers and may experience bleeding symptoms. Globally, haemophilia affects over 836,000 males, yet fewer than half are diagnosed and registered. 1)
Read our factsheet for more information about haemophilia -
What are haemoglobinopathies?
Haemoglobinopathies are blood disorders that affect the structure or production of haemoglobin – a condition that is lifelong, genetically inherited, and often underdiagnosed. The most common forms are sickle cell disease (SCD) and thalassaemia. According to the World Health Organization and Thalassaemia International Federation, an estimated 500,000 to 600,000 babies are born each year with SCD or thalassaemia. 2) 3)
Read our factsheets for more information about sickle cell disease
You can be part of this journey!
By providing access to care and treatment, NNHF can prevent disability and death, and significantly improve the quality of life of people living with haemophilia or haemoglobinopathies.
Together with you, we can do even more!
